| Autor: |
Sabine Schmid, Sierra Cheng, Simren Chotai, Miguel Garcia, Luna Zhan, Katrina Hueniken, Karmugi Balaratnam, Khaleeq Khan, Devalben Patel, Benjamin Grant, Roula Raptis, M. Catherine Brown, Wei Xu, Patrick Moriarty, Frances A. Shepherd, Adrian G. Sacher, Natasha B. Leighl, Penelope A. Bradbury, Geoffrey Liu |
| Rok vydání: |
2023 |
| Předmět: |
|
| Zdroj: |
Clinical Lung Cancer. 24:40-50 |
| ISSN: |
1525-7304 |
| DOI: |
10.1016/j.cllc.2022.09.007 |
| Popis: |
OBJECTIVES This real-world analysis describes treatment patterns, sequencing and clinical effectiveness, toxicities, and health utility outcomes in advanced-stage, incurable ALK-positive NSCLC patients across five different ALK-TKIs. MATERIALS AND METHODS Clinicodemographic, treatment, and toxicity data were collected retrospectively in patients with advanced-stage ALK-positive NSCLC at Princess Margaret Cancer Centre. Patient-reported symptoms, toxicities, and health utilities were collected prospectively. RESULTS Of 148 ALK-positive NSCLC patients seen July 2009-May 2021, median age was 58.9 years; 84 (57%) were female; 112 (76%) never-smokers; 54 (47%) Asian and 40 (35%) white; 139 (94%) received at least one ALK-TKI: crizotinib (n = 74; 54%) and alectinib (n = 61; 44%) were administered mainly as first-line ALK-TKI, ceritinib, brigatinib and lorlatinib were administered primarily after previous ALK-TKI failure. Median overall survival (OS) was 54.0 months; 31 (21%) patients died within two years of advanced-stage diagnosis. Treatment modifications were observed in 35 (47%) patients with crizotinib, 19 (61%) with ceritinib, 41 (39%) with alectinib, 9 (41%) with brigatinib and 8 (30%) with lorlatinib. Prevalence of dose modifications and self-reported toxicities were higher with early versus later generation ALK-TKIs (P |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect